People with type 2 diabetes are being sought to participate in a New York Hospital Queens (NYHQ) study that is examining a new treatment.
To participate in the study, the individual must be between 18 and 75 years of age. During their participation, they will take an oral agent to control their diabetes.
The focus of the study, now in its second phase, is the generic drug, salsalate, which is frequently used to treat arthritis. During this part of the study, the “efficacy and safety in a larger group of people over a longer time period than the first phase” will be evaluated.
The study has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases.
“Because adults with diabetes are two to four times more likely to have heart disease or suffer a stroke than people without diabetes, the federal government and diabetes researchers have long been interested in finding a safe, effective and inexpensive way to treat diabetes,” said Dr. Daniel Lorber, the director of NYHQ’s Division of Endocrinology, who is also the associate director of The Theresa and Eugene M. Lang Center for Research and Education.
Lorber is also the principal investigator for the study taking place at NYHQ.
“This is an intriguing study as it may help us understand the role that inflammation plays in the development of diabetes,” Lorber said. “We are pleased to be collaborating in this important national study.”
Anyone interested in participating in the study can find out more information by contacting NYHQ’s Lang Center for Research and Education at 718-670-2914.
